These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 32666202)

  • 1. Pilot study of tenofovir disoproxil fumarate and pegylated interferon-alpha 2a add-on therapy in Japanese patients with chronic hepatitis B.
    Matsumoto A; Nishiguchi S; Enomoto H; Tanaka Y; Shinkai N; Okuse C; Kang JH; Matsui T; Miyase S; Yatsuhashi H; Nagaoka S; Kanda T; Enomoto M; Yamada R; Hiramatsu N; Saito S; Takaguchi K; Ito K; Masaki T; Morihara D; Tsuge M; Chayama K; Ikeda F; Kagawa T; Kondo Y; Murata K; Tanaka E
    J Gastroenterol; 2020 Oct; 55(10):977-989. PubMed ID: 32666202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Add-on pegylated interferon augments hepatitis B surface antigen clearance
    Wu FP; Yang Y; Li M; Liu YX; Li YP; Wang WJ; Shi JJ; Zhang X; Jia XL; Dang SS
    World J Gastroenterol; 2020 Apr; 26(13):1525-1539. PubMed ID: 32308352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B.
    Marcellin P; Ahn SH; Chuang WL; Hui AJ; Tabak F; Mehta R; Petersen J; Lee CM; Ma X; Caruntu FA; Tak WY; Elkhashab M; Lin L; Wu G; Martins EB; Charuworn P; Yee LJ; Lim SG; Foster GR; Fung S; Morano L; Samuel D; Agarwal K; Idilman R; Strasser SI; Buti M; Gaeta GB; Papatheodoridis G; Flisiak R; Chan HL
    Aliment Pharmacol Ther; 2016 Nov; 44(9):957-966. PubMed ID: 27629859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HBsAg clearance in chronic hepatitis B patients with add-on pegylated interferon alfa-2a to ongoing tenofovir treatment: A randomized controlled study.
    Al Ashgar H; Peedikayil MC; Al Quaiz M; Al Sohaibani F; Al Fadda A; Khan MQ; Thoralsson E; Al Thawadi S; Al Jedai A; Al Kahtani K
    Saudi J Gastroenterol; 2017; 23(3):190-198. PubMed ID: 28611343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis.
    Ahn SH; Marcellin P; Ma X; Caruntu FA; Tak WY; Elkhashab M; Chuang WL; Tabak F; Mehta R; Petersen J; Guyer W; Jump B; Chan A; Subramanian M; Crans G; Fung S; Buti M; Gaeta GB; Hui AJ; Papatheodoridis G; Flisiak R; Chan HLY
    Dig Dis Sci; 2018 Dec; 63(12):3487-3497. PubMed ID: 30136045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy.
    Bazinet M; Pântea V; Placinta G; Moscalu I; Cebotarescu V; Cojuhari L; Jimbei P; Iarovoi L; Smesnoi V; Musteata T; Jucov A; Dittmer U; Krawczyk A; Vaillant A
    Gastroenterology; 2020 Jun; 158(8):2180-2194. PubMed ID: 32147484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: a pilot study.
    Tatsukawa Y; Tsuge M; Kawakami Y; Hiyama Y; Murakami E; Kurihara M; Nomura M; Tsushima K; Uchida T; Nakahara T; Miki D; Kawaoka T; Abe-Chayama H; Imamura M; Aikata H; Ochi H; Hayes CN; Kawakami H; Chayama K
    Antivir Ther; 2018; 23(8):639-646. PubMed ID: 29856363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy.
    Matsumoto A; Nishiguchi S; Enomoto H; Kang JH; Tanaka Y; Shinkai N; Kurosaki M; Enomoto M; Kanda T; Yokosuka O; Yatsuhashi H; Nagaoka S; Okuse C; Kagawa T; Mine T; Takaguchi K; Saito S; Hino K; Ikeda F; Sakisaka S; Morihara D; Miyase S; Tsuge M; Chayama K; Hiramatsu N; Suzuki Y; Murata K; Tanaka E
    J Gastroenterol; 2018 Feb; 53(2):247-257. PubMed ID: 28634723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline HBsAg and HBcrAg titres allow peginterferon-based 'precision medicine' in HBeAg-negative chronic hepatitis B patients.
    Martinot-Peignoux M; Lapalus M; Maylin S; Boyer N; Castelnau C; Giuily N; Pouteau M; Moucari R; Asselah T; Marcellin P
    J Viral Hepat; 2016 Nov; 23(11):905-911. PubMed ID: 27375231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unconventional T cells in chronic hepatitis B patients on long-term suppressive therapy with tenofovir followed by a Peg-IFN add-on strategy: A randomized study.
    Cannizzo ES; Tincati C; Binda F; Ronzi P; Cazzaniga FA; Antinori S; d'Arminio Monforte A; Marchetti G; Milazzo L
    J Viral Hepat; 2018 Apr; 25(4):381-390. PubMed ID: 29091327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Pegylated Interferon Plus Tenofovir Combination on Higher Hepatitis B Surface Antigen Loss in Treatment-naive Patients With Hepatitis B e Antigen -positive Chronic Hepatitis B: A Real-world Experience.
    Hu C; Song Y; Tang C; Li M; Liu J; Liu J; Liao M; Zhou F; Zhang YY; Zhou Y
    Clin Ther; 2021 Mar; 43(3):572-581.e3. PubMed ID: 33516527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive role of serum HBsAg and HBcrAg kinetics in patients with HBeAg-negative chronic hepatitis B receiving pegylated interferon-based therapy.
    Chuaypen N; Posuwan N; Chittmittraprap S; Hirankarn N; Treeprasertsuk S; Tanaka Y; Shinkai N; Poovorawan Y; Tangkijvanich P
    Clin Microbiol Infect; 2018 Mar; 24(3):306.e7-306.e13. PubMed ID: 28750917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B.
    Marcellin P; Ahn SH; Ma X; Caruntu FA; Tak WY; Elkashab M; Chuang WL; Lim SG; Tabak F; Mehta R; Petersen J; Foster GR; Lou L; Martins EB; Dinh P; Lin L; Corsa A; Charuworn P; Subramanian GM; Reiser H; Reesink HW; Fung S; Strasser SI; Trinh H; Buti M; Gaeta GB; Hui AJ; Papatheodoridis G; Flisiak R; Chan HL;
    Gastroenterology; 2016 Jan; 150(1):134-144.e10. PubMed ID: 26453773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peg-interferon alpha add-on Tenofovir disoproxil fumarate achieved more HBsAg loss in HBeAg-positive chronic hepatitis B naïve patients.
    Li J; Qu L; Sun X; Liu Y; Gong Q; Yu D; Zhang D; Jiang J; Chen J; Wei D; Han Y; Gao Y; Zhang Q; She W; Chen L; Zhang J; Zhang X
    J Viral Hepat; 2021 Oct; 28(10):1381-1391. PubMed ID: 34228855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
    Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
    Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial.
    de Niet A; Jansen L; Stelma F; Willemse SB; Kuiken SD; Weijer S; van Nieuwkerk CMJ; Zaaijer HL; Molenkamp R; Takkenberg RB; Koot M; Verheij J; Beuers U; Reesink HW
    Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):576-584. PubMed ID: 28522204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HBcrAg values may predict virological and immunological responses to pegIFN-α in NUC-suppressed HBeAg-negative chronic hepatitis B.
    Vecchi A; Rossi M; Tiezzi C; Fisicaro P; Doselli S; Gabor EA; Penna A; Montali I; Ceccatelli Berti C; Reverberi V; Montali A; Fletcher SP; Degasperi E; Sambarino D; Laccabue D; Facchetti F; Schivazappa S; Loggi E; Coco B; Cavallone D; Rosselli Del Turco E; Massari M; Pedrazzi G; Missale G; Verucchi G; Andreone P; Brunetto MR; Lampertico P; Ferrari C; Boni C
    Gut; 2024 Sep; 73(10):1737-1748. PubMed ID: 39033025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegylated interferon-α-2b combined with tenofovir disoproxil fumarate, granulocyte-macrophage colony-stimulating factor, and hepatitis B vaccine treatment for naïve HBeAg-positive chronic hepatitis B patients: A prospective, multicenter, randomized controlled study.
    Lian J; Kuang W; Jia H; Lu Y; Zhang X; Ye C; Gu J; Lv Y; Yu J; Zhang Y; Lu X; Zhao Y; Yang D; Wang K; Zhao P; Yu Y; Bai L; Zhang J; Zhang X; Yang Y
    J Med Virol; 2022 Nov; 94(11):5475-5483. PubMed ID: 35836102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B.
    Kittner JM; Sprinzl MF; Grambihler A; Weinmann A; Schattenberg JM; Galle PR; Schuchmann M
    J Clin Virol; 2012 May; 54(1):93-5. PubMed ID: 22365367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The expression of interleukin-1β in patients with chronic hepatitis B treated with pegylated-interferon-alpha combined with tenofovir disoproxil fumarate and monotherapy.
    Hu X; Luo H; Tan G; Li Y; Qin B
    BMC Gastroenterol; 2023 May; 23(1):163. PubMed ID: 37208599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.